Crossmark

Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma

Crossref DOI link: https://doi.org/10.1186/s12860-018-0180-1

Published Online: 2018-12-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Skoko, Josip

Rožanc, Jan

Charles, Emilie M.

Alexopoulos, Leonidas G.

Rehm, Markus https://orcid.org/0000-0001-6149-9261
Funding

Funding for this research was provided by:

Horizon 2020 Framework Programme (642295)

Horizon 2020 (642295)

Health Research Board (HRA-POR-2013-245, HRA-POR-2015-1091)
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 30 July 2018

Accepted: 11 December 2018

First Online: 27 December 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.